Gavreto is recommended as a first-line treatment for metastatic RET fusion-positive, metastatic non-small cell lung cancer, ...

Significant alterations in the structure and cellular composition of the distal lung are a defining characteristic of ...

Residual cancer can remain undetected despite clear scans, potentially leading to worse outcomes and higher risks of ...

Radiotherapy, especially a form known as stereotactic ablative radiotherapy (SABR), is widely used to treat cancers in the ...

While radiotherapy is a highly effective cancer treatment — useful for about 60 per cent of all cancers — it may lead to ...

The following is a summary of "Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma implicate the needs for tailored treatment strategies," published in the March ...

BUFFALO, NY - March 21, 2025 – A new editorial was published in Oncotarget, Volume 16, on March 13, 2025, titled “ No disease ...

CNS Pharmaceuticals' Berubicin trial results show a favorable safety profile with no cardiotoxicity and comparable efficacy ...

"Residual cancer is identified on histology in 40% of lung, 57–69% of renal cell, 7.7–47.6% of prostate and 0–86.7% of hepatocellular carcinoma." ...

A recent analysis shows that additional invasive staging modalities lead to relevant changes in target volume in some patients with NSCLC but do not impact survival.